avatrombopag maleate · Akarx Inc · NDA 210238
Doptelet
Earliest generic entry, as listed
24 Jul 2032
Blocked by exclusivity: ODE-548.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 7638536 | substance, product | 28 Jul 2027 |
Exclusivities · 2 unexpired
| ODE-548 | orphan drug (7 years) | 24 Jul 2032 |
| I-974 | new indication (3 years) | 24 Jul 2028 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 210238 · 001 · RLD | tablet, oral | EQ 20MG BASE | 24 Jul 2032 |
Expired or delisted (1)
- ODE-246 · 26 Jun 2026